Patents Issued in February 18, 2016
  • Publication number: 20160045555
    Abstract: An isolated stem cell that has been modified to provide, enhance orcontain the functional characteristics of the sarcoplasmic reticulum (SR). The isolated stem cells are modified in one or more of the following manners: by expressing a calcium channel protein; by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca2+-ATPase (SERCA) protein; by inhibiting or downregulating expression of the Na+/Ca2+ exchanger (NCX) protein; by expressing a calcium handling protein; by expressing a transverse (t)-tubule; and/or by expressing a transverse (t)-tubule biogenic protein. After the cell has been modified, it may be expanded to a substantially homogenous population of these cells or alternatively, differentiated to a more mature cell type. Compositions containing these cells and population of cells are also provided by this invention.
    Type: Application
    Filed: June 1, 2015
    Publication date: February 18, 2016
    Inventors: Ronald Li, Chung-wah Siu, Deborah K. Lieu, Jing Liu
  • Publication number: 20160045556
    Abstract: The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi, preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi, preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 18, 2016
    Applicant: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh SAHA, Shibin ZHOU, Bert VOGELSTEIN, Kenneth W. KINZLER
  • Publication number: 20160045557
    Abstract: The invention relates to the use of lactic acid bacteria, for use in modifying the enteric nervous system and more particularly in treating and/or preventing intestinal disorders such as constipation and/or irritable bowel disease.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Applicant: COMPAGNE GERVAIS DANONE
    Inventors: Sophie Legrain-Raspaud, Gianfranco Grompone, Sandrine Capronnier, Isabelle Chambaud, Tamara Smokvina, Marie-Christine Degivry, Biliana Lesic, Michel Neunlist
  • Publication number: 20160045558
    Abstract: A composition including Cuscuta japonica Choisy extract, or the extract of Rehmannia glutinosa Libschitz var. purpurea MAKINO and Cuscuta japonica Choisy is provided. The composition, which can be a pharmaceutical or food composition, is useful for for preventing, ameliorating, or treating hearing loss. A method for ameliorating, preventing, or treating hearing loss, in particular, acoustic trauma, temporary or permanent hearing loss by effectively inhibiting the threshold shift induced by noise and the likes is disclosed.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Applicant: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
    Inventors: Tong Ho KANG, Bin Na HONG
  • Publication number: 20160045559
    Abstract: The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of useful for promoting, managing or improving bone health, cartilage health or both, or for preventing or treating a bone disorder, cartilage disorder or both. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other bone and cartilage management agents, such as calcium, magnesium, zinc, boron, vitamin D, vitamin K, glucosamine and/or chondroitin compounds, non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, neuropathic pain relief agents, or the like.
    Type: Application
    Filed: June 16, 2015
    Publication date: February 18, 2016
    Inventors: Lidia Alfaro Brownell, Min Chu, Mei-Feng Hong, Eu-Jin Hyun, Qi Jia, Ping Jiao, Hyun-Jin Kim, Mi-Ran Kim, Tae-Woo Kim, Young-Chul Lee, Jeong-Bum Nam, Mesfin Yimam
  • Publication number: 20160045560
    Abstract: A weight loss product comprises a mixture of Alchemilla vulgaris, Olea europaea, Cuminum cyminum, and Mentha longiflora (in the weight proportion 12:10:5:4), to which additional ingredients have been added to increase weight loss efficacy.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Inventors: Shawn Shirazi, James Akrong, Phil Apong, Raza Bashir, Craig Wissent
  • Publication number: 20160045561
    Abstract: The present invention relates to an antioxidatively active composition including at least one polyphenol rich plant extract; at least one porphyrine, and at least one additional compound from the group of stilbenoids, and the use thereof.
    Type: Application
    Filed: March 19, 2014
    Publication date: February 18, 2016
    Inventors: Sabine Larsen-Vefring, Christian Lendzian, Monika Gassen
  • Publication number: 20160045562
    Abstract: The present invention relates to an isolated peptide for use in the treatment of cancer consisting of 12 to 50 amino acid residues comprising—at least two beta-strands, or—at least two alpha-helices or—at least one beta-strand and at least one alpha-helix, —wherein said beta-strands and/or alpha-helices are preferably separated from each other by at least one turn, wherein the peptide has a net positive charge of +7 or more; —wherein said peptide comprises at least one peptide moiety having amino acid sequence (X1)M-X2-(X3)P-X4-(X5)Q-X6-(X7)S or the reverse sequence thereof, wherein X1 is a hydrophobic amino acid, preferably selected from the group consisting of phenylalanine (Phe), alanine (Ala), leucine (Leu) and valine (Val), X2 is a hydrophobic amino acid, preferably tryptophan (Trp), X3 is selected from the group consisting of alanine (Ala), arginine (Arg), glutamine (Gin), asparagine (Asn), proline (Pro), isoleucine (lie), leucine (Leu) and valine (Val), X4 is selected from the group consisting of isole
    Type: Application
    Filed: January 9, 2014
    Publication date: February 18, 2016
    Applicant: OSTERREICHISCHE AKADEME DER WISSENSCHAFTEN
    Inventors: Dagmar Zweytick, Karl Lohner, Sabrina Riedl
  • Publication number: 20160045563
    Abstract: A muscle atrophy-preventing agent includes a milk-derived basic protein fraction and/or a decomposed product of the milk-derived basic protein fraction as an active ingredient. The muscle atrophy-preventing agent is remarkably effective in preventing muscle mass decline and increasing muscle mass, and thus is useful in preventing and treating various muscle diseases, such as sarcopenia and disuse muscle atrophy.
    Type: Application
    Filed: March 25, 2014
    Publication date: February 18, 2016
    Applicant: MEGMILK SNOW BRAND CO., LTD.
    Inventors: Yuko ISHIDA, Yoshikazu MORITA, Ken KATOH, Toshiya KOBAYASHI, Yuki MIZUNO, Aiko OHMACHI
  • Publication number: 20160045564
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Application
    Filed: May 26, 2015
    Publication date: February 18, 2016
    Inventors: Jesper R. Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Publication number: 20160045565
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Application
    Filed: December 26, 2013
    Publication date: February 18, 2016
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: Lei LING, Jian LUO
  • Publication number: 20160045566
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.
    Type: Application
    Filed: October 31, 2014
    Publication date: February 18, 2016
    Inventors: Lisa Arleen Purcell Ngambo, Sarah J. Higgins, Kevin C. Kain
  • Publication number: 20160045567
    Abstract: The invention relates to methods and compositions comprising a macrophage colony stimulating factor (M-CSF) polypeptide or an agonist of the M-CSF receptor for preventing or treating myeloid cytopenia and related complications (such as infections) in a patient in need thereof (such as a patient undergoing hematopoietic stem cell transplantation).
    Type: Application
    Filed: April 9, 2014
    Publication date: February 18, 2016
    Inventor: Michael SIEWEKE
  • Publication number: 20160045568
    Abstract: The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Inventors: Jonas FRANSSON, Ebba FLORIN-ROBERTSSON
  • Publication number: 20160045569
    Abstract: The present invention is directed to an endogenous vaccine targeted to a cancer or an infectious disease.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 18, 2016
    Applicant: Neumedicines, Inc.
    Inventor: Lena A. Basile
  • Publication number: 20160045570
    Abstract: Methods, assays and kits for the identification, assessment and/or treatment of a subject having multiple sclerosis (MS) (e.g., a patient with relapsing-remitting multiple sclerosis (RRMS)) are disclosed.
    Type: Application
    Filed: July 14, 2015
    Publication date: February 18, 2016
    Inventors: Steven Bushnell, Alexander Michael Buko, Eric Taylor Whalley, Christopher Stebbins, Zhenming Zhao, Diego Cadavid
  • Publication number: 20160045571
    Abstract: Methods and compositions for treating or preventing cognitive disorders in mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-1B signaling pathway involving gamma-carboxylase and osteocalcin, e.g., by administration of undercarboxylated/uncarboxylated osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, cognitive loss due to neurodegeneration associated with aging, anxiety, depression, memory loss, learning difficulties, and cognitive disorders associated with food deprivation during pregnancy.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Inventors: Gerard KARSENTY, Franck OURY
  • Publication number: 20160045572
    Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 18, 2016
    Inventors: Scott Shandler, Samuel H. Gellman, John M. Gledhill
  • Publication number: 20160045573
    Abstract: The present invention relates to a method using fibrinogen-coated albumin spheres for treating a patient infected with a hemorrhagic virus. A suspension of protein nanoparticle containing submicron protein spheres is prepared and administered to the patient. The protein spheres are bound with fibrinogen molecules in vitro or in vivo. The fibrinogen-coated albumin spheres provide improved hemostatic function of a residual concentration of platelets of the patient resulting in decreasing mortality rate or decreasing morbidity of the patient. The fibrinogen-coated albumin spheres protect an endothelial function of an endothelial cell of a blood vessel of the patient resulting in improved permeability control across predetermined tissues in the patient, thereby counteracting an effect of the hemorrhagic virus on a wall of the blood vessel.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventor: Richard C.K. Yen
  • Publication number: 20160045574
    Abstract: An enzymatically-active ribonuclease is combined with a vehicle that does not unacceptably interfere with such enzymatic activity and applied externally. Advantageously, the ribonuclease is ranpirnase. The vehicle can be a liquid, a gel, an ointment, or a serum, and can also be an approved sexual lubricant.
    Type: Application
    Filed: August 18, 2014
    Publication date: February 18, 2016
    Applicant: TAMIR BIOTECHNOLOGY, INC.
    Inventors: Jamie Sulley, Luis Squiquera
  • Publication number: 20160045575
    Abstract: The present disclosure relates to methods, systems, and compositions to repair one or more mutations in a Factor VIII gene sequence of a subject by introducing into a cell of the subject one or more polynucleotides encoding a DNA scission enzyme (DNA-SE) and one or more repair vehicles (RVs) containing at least a cDNA-repair sequence (RS) such that insertion of the cDNA-RS through homologous recombination with the F8 gene of the subject (sF8) provides a repaired F8 gene (rF8), the repaired F8 gene (rF8) upon expression forming a functional FVIII conferring improved coagulation functionality to the FVIII protein encoded by the sF8. The present disclosure also relates to cells derived using the methods, systems and compositions described.
    Type: Application
    Filed: June 11, 2015
    Publication date: February 18, 2016
    Inventor: Tom E. HOWARD
  • Publication number: 20160045576
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Application
    Filed: October 23, 2015
    Publication date: February 18, 2016
    Inventors: Joan M. Fallon, Matthew Heil
  • Publication number: 20160045577
    Abstract: A method of treating circadian rhythm disorders includes identifying a subject with a circadian rhythm disorder or at least one symptom of a circadian rhythm disorder and administering an effective amount of a composition comprising a botulinum toxin and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of a circadian rhythm disorder.
    Type: Application
    Filed: September 14, 2015
    Publication date: February 18, 2016
    Inventor: Gary E. Borodic
  • Publication number: 20160045578
    Abstract: The present invention provides isolated polypeptides comprising the amino acid sequence of SEQ ID NO: 1, or a fragment, variant, derivative or fusion thereof which is capable of binding specifically to and/or lysing cells of Clostridium difficile, and means for producing the same, with the proviso that the fragment, variant, derivative or fusion is not a naturally occurring lysin of a bacteriophage of Clostridium difficile. The invention further provides methods for killing bacterial cells, such as cells of Clostridium difficile, and for diagnosing, treating and preventing diseases and conditions associated with infection of the same. The invention also provides diagnostic kits for use in such methods.
    Type: Application
    Filed: March 27, 2015
    Publication date: February 18, 2016
    Inventors: Michael Gasson, Melinda Mayer, Arjan Narbad
  • Publication number: 20160045579
    Abstract: Methods and compositions for treating a patient who has recently developed diabetes are provided. The methods can include administering a tolerance-restoring agent to the patient and simultaneously administering intensive insulin therapy.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 18, 2016
    Inventor: Maria Koulmanda
  • Publication number: 20160045580
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Application
    Filed: July 27, 2015
    Publication date: February 18, 2016
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Publication number: 20160045581
    Abstract: The invention relates to helminthic parasite preparations and their use for treatment or prevention of GVHD in a subject that has undergone a transplant. The invention also related to helminthic parasite preparations and their use for prevention of GVHD in a subject prior to a transplant.
    Type: Application
    Filed: April 10, 2015
    Publication date: February 18, 2016
    Inventors: Mirac Nedim Ince, David E. Elliott, George J. Weiner
  • Publication number: 20160045582
    Abstract: The present invention provides a compound represented by the formula (1): wherein Xa and Ya are each a single bond or the like, cancer antigen peptide A is an MHC class I-restricted cancer antigen peptide, and R1 is a hydrogen atom; a group represented by the formula (2): wherein Xb and Yb are each a single bond or the like, and cancer antigen peptide B is different from the cancer antigen peptide A and is an MHC class I or II-restricted cancer antigen peptide; a group represented by the formula (3): wherein Xc and Yc are each a single bond or the like, and cancer antigen peptide C is an MHC class II-restricted cancer antigen peptide; or cancer antigen peptide D, wherein the cancer antigen peptide D is an MHC class I or II-restricted cancer antigen peptide containing one cysteine residue, or a salt thereof, for example.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 18, 2016
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi BAN, Yukihiro NISHIO, Masashi GOTO, Yosuke TAKANASHI
  • Publication number: 20160045583
    Abstract: The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen.
    Type: Application
    Filed: July 29, 2015
    Publication date: February 18, 2016
    Inventor: Eckhard R. Podack
  • Publication number: 20160045584
    Abstract: The present application provides a vaccine composition comprising: bacteria engineered to express at least one N-glycan of Campylobacter, such as C. jejuni for example, or an N-glycan derivative thereof on its cell surface; and one or more of a physiologically acceptable diluent, excipient, adjuvant or carrier. The bacteria is Escherichia coli, Salmonella or any suitable bacteria that offers sufficient expression and improved immunogenic response. The vaccine composition can be formulated for administration to animals, such as poultry, including chickens.
    Type: Application
    Filed: April 4, 2014
    Publication date: February 18, 2016
    Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Christine Szymanski, Harald Nothaft
  • Publication number: 20160045585
    Abstract: This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material comprises a microorganism. In particular, the invention relates to compositions comprising a microorganism selected from live, killed, attenuated and inactivated microorganisms. The matrix material may also comprise a surfactant and may further comprise an adjuvant. The invention further relates to the manufacture and use of such compositions, and to other subject matter.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Applicant: SIGMOID PHARMA LIMITED
    Inventors: Ivan Coulter, Bernard Francis McDonald, Vincenzo Aversa, Monica Torres Rosa
  • Publication number: 20160045586
    Abstract: The disclosure relates to generally to the field of toxin inactivation. More specifically, it relates to clostridial toxins, methods of inactivating these toxins and compositions (e.g., vaccines) comprising toxoids (e.g., produced by these methods). Provided are methods of producing a C. difficile toxoid comprising inactivating a C. difficile toxin with formaldehyde. Toxoids prepared by these methods are stable at high temperature (e.g., 37° C.) and remain non-cytotoxic with minimal residual formaldehyde.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Applicant: Sanofi Pasteur, Inc.
    Inventor: Steven Hauser
  • Publication number: 20160045587
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Application
    Filed: September 21, 2015
    Publication date: February 18, 2016
    Inventors: Camille LOCHT, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Publication number: 20160045588
    Abstract: The present invention provides in part fusion proteins derived from Chlamydia spp. The present invention also provides in part methods for treating or preventing Chlamydia infection using the fusion proteins.
    Type: Application
    Filed: February 6, 2015
    Publication date: February 18, 2016
    Inventors: Robert C. BRUNHAM, Karuna P. KARUNAKARAN, Hong YU
  • Publication number: 20160045589
    Abstract: The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 18, 2016
    Inventors: David WEINER, Jian YAN, Karuppiah MUTHUMANI, Niranjan Y. SARDESAI
  • Publication number: 20160045590
    Abstract: The present invention provides, among other things, improved influenza vaccines based on hemagglutinins containing one or more alkylated cysteine residues. In particular, the present invention provides influenza vaccines containing hemagglutinins treated with an alkylating agent and methods of making the same. Inventive influenza vaccines provided by the present invention have a remarkable ability to retain potency as determined by Single Radial Immunodiffusion (SRID) assay upon storage.
    Type: Application
    Filed: August 18, 2015
    Publication date: February 18, 2016
    Inventors: Brooke S. Milner, Jonathan Haines, Steven L. Hauser, Janet Beebe Poli
  • Publication number: 20160045591
    Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.
    Type: Application
    Filed: January 23, 2015
    Publication date: February 18, 2016
    Inventors: Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
  • Publication number: 20160045592
    Abstract: Disclosed are yeast-based immunotherapeutic compositions, human immunodeficiency virus (HIV) antigens, and fusion proteins for the treatment and/or prevention of HIV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HIV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HIV and/or symptoms thereof.
    Type: Application
    Filed: March 26, 2014
    Publication date: February 18, 2016
    Inventors: Thomas H. KING, David APELIAN
  • Publication number: 20160045593
    Abstract: The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods.
    Type: Application
    Filed: August 21, 2015
    Publication date: February 18, 2016
    Inventors: Luc Willems, Karina Trono
  • Publication number: 20160045594
    Abstract: A synthetic polypeptide vaccine is employed for directed targeting of an individual's immune response to an antigen of interest. The synthetic polypeptide contains a carrier epitope specific for open conformers of an individual's MHC-I molecules in the presence of HLA-F, and also contains an effector epitope which elicits an immune response to the antigen of interest. The effect- or epitope may modulates an immune response to a tumor, pathogen, or autoantigen associated with an autoimmune disorder. The present vaccine exploits a role for the interaction between HLA-F and open conformers of MHC-I in the uptake of extracellular antigen for cross presentation.
    Type: Application
    Filed: March 27, 2014
    Publication date: February 18, 2016
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Daniel E. Geraghty, Jodie P. Goodridge
  • Publication number: 20160045595
    Abstract: A nanoparticle comprising at least one sterol, e.g. cholesterol and a component from Quillaja Saponaria Molina (QuilQ) selected from quillaja saponin, characterized in that said nanoparticles do not comprise a phospholipid and in that the sterol molecule is bound by a hydrophobic bond between a hydroxyl group of the sterol and terpene moieties in a Quil A micelle and by an hydrophilic ester bond between a sterol OH? and COOH? or aldehyde groups in the QuilA micelle. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.
    Type: Application
    Filed: March 31, 2014
    Publication date: February 18, 2016
    Applicant: Moreinx AB
    Inventors: Bror Morein, Saideh Berenjian, Kafei Hu
  • Publication number: 20160045596
    Abstract: Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
    Type: Application
    Filed: August 5, 2015
    Publication date: February 18, 2016
    Inventors: Elena Geretti, Victor Moyo, Joseph G. Reynolds, Thomas Wickham
  • Publication number: 20160045597
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: August 14, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Emily Rana CORSE, Olivier FREYTAG, Christian GERDES, Marine LE CLECH, Hyam LEVITSKY, Marion OTT, Martin STERN, Wei XU
  • Publication number: 20160045598
    Abstract: Methods for treating cancer using a combination of an inhibitor of the sonic hedgehog signaling pathway (e.g., LDE225) with radiation and a tumor antigen-specific monoclonal antibody (e.g., heat shock protein (HSP) glucose regulated protein of 94000 daltons (Grp94)-specific mAb W9, or chondroitin sulfate proteoglycan 4 (CSPG4)-targeted mAbs), or with a BRAF inhibitor, e.g., in BRAF inhibitor resistant cancers.
    Type: Application
    Filed: April 3, 2014
    Publication date: February 18, 2016
    Inventors: Francesco Sabbatino, Yangyang Wang, Xinhui Wang, Steven Isakoff, Cristina Ferrone, Joe Schwab, Soldano Ferrone
  • Publication number: 20160045599
    Abstract: Aspects of the disclosure include devices, systems and methods for optogenetic modulation of action potentials in target cells. The subject devices include light-generating devices, control devices, and delivery devices for delivering vectors to target cells. The subject systems include light-activated proteins, response proteins, nucleic acids comprising nucleotide sequences encoding these proteins, as well as expression systems that facilitate expression of these proteins in target cells. Also provided are methods of using the subject devices and systems to optogenetically inhibit and intercept action potentials in target cells, e.g., to treat a neurological or psychiatric condition in a human or non-human animal subject.
    Type: Application
    Filed: April 29, 2014
    Publication date: February 18, 2016
    Applicant: The Board of Trustees of theLeland Stanford Junior University
    Inventors: Karl A. Deisseroth, Emily Anne Ferenczi, Peter Hegemann
  • Publication number: 20160045600
    Abstract: The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications.
    Type: Application
    Filed: July 15, 2015
    Publication date: February 18, 2016
    Inventors: Xavier DE MOLLERAT DU JEU, Nektaria ANDRONIKOU
  • Publication number: 20160045601
    Abstract: Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.
    Type: Application
    Filed: July 16, 2015
    Publication date: February 18, 2016
    Applicant: DURECT CORPORATION
    Inventors: Jeremy C. WRIGHT, Felix Theeuwes, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK
  • Publication number: 20160045602
    Abstract: Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Inventors: Peter Jarrett, Rami El-Hayek, Amarpreet S. Sawhney
  • Publication number: 20160045603
    Abstract: A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.
    Type: Application
    Filed: January 14, 2014
    Publication date: February 18, 2016
    Applicant: ASTELLAS PHARMA EUROPE LTD.
    Inventors: Yoshiyuki Murakami, Hikaru Saito
  • Publication number: 20160045604
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Application
    Filed: August 13, 2015
    Publication date: February 18, 2016
    Applicants: Synthetic Biologics, Inc., Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher